Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

Next Previous
Trial Profile

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emzadirib (Primary) ; Bendamustine; Capecitabine; Gemcitabine; Rituximab
  • Indications Adenocarcinoma; Advanced breast cancer; B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Carcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; HER2 negative breast cancer; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Cyteir Therapeutics

Most Recent Events

  • 24 Dec 2024 Status changed from active, no longer recruiting to completed.
  • 23 Sep 2024 Planned End Date changed from 30 Dec 2024 to 30 Apr 2025.
  • 23 Sep 2024 Planned primary completion date changed from 30 Jul 2024 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top